FLGT Stock - Fulgent Genetics, Inc.
Unlock GoAI Insights for FLGT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $283.47M | $289.21M | $618.97M | $992.58M | $421.71M |
| Gross Profit | $107.22M | $104.46M | $366.90M | $777.05M | $331.90M |
| Gross Margin | 37.8% | 36.1% | 59.3% | 78.3% | 78.7% |
| Operating Income | $-73,918,000 | $-195,529,000 | $178.53M | $675.95M | $290.16M |
| Net Income | $-42,708,000 | $-167,825,000 | $143.40M | $507.36M | $214.31M |
| Net Margin | -15.1% | -58.0% | 23.2% | 51.1% | 50.8% |
| EPS | $-1.41 | $-5.63 | $4.76 | $17.13 | $9.44 |
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 5th 2025 | UBS | Upgrade | Buy | $30 |
| December 7th 2023 | UBS | Initiation | Neutral | $35 |
| December 8th 2022 | Piper Sandler | Downgrade | Neutral | $40← $65 |
| November 18th 2022 | Raymond James | Initiation | Outperform | $45 |
| August 25th 2022 | Credit Suisse | Initiation | Outperform | $65 |
Earnings History & Surprises
FLGTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 30, 2026 | — | — | — | — |
Q1 2026 | Feb 27, 2026 | $-0.12 | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.24 | $0.14 | +158.3% | ✓ BEAT |
Q3 2025 | Aug 1, 2025 | $-0.23 | $0.07 | +130.4% | ✓ BEAT |
Q2 2025 | May 2, 2025 | $-0.19 | $0.04 | +121.1% | ✓ BEAT |
Q1 2025 | Feb 28, 2025 | $-0.31 | $0.04 | +112.9% | ✓ BEAT |
Q4 2024 | Nov 8, 2024 | $-0.19 | $0.31 | +263.2% | ✓ BEAT |
Q3 2024 | Aug 2, 2024 | $-0.31 | $0.15 | +148.4% | ✓ BEAT |
Q2 2024 | May 3, 2024 | $-0.33 | $-0.01 | +97.0% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.30 | $0.28 | +193.3% | ✓ BEAT |
Q4 2023 | Nov 3, 2023 | $-0.33 | $-0.39 | -18.2% | ✗ MISS |
Q3 2023 | Aug 4, 2023 | $-0.33 | $-0.08 | +75.8% | ✓ BEAT |
Q2 2023 | May 5, 2023 | $-0.45 | $-0.22 | +51.1% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.56 | $-0.48 | +14.3% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $0.17 | $0.32 | +88.2% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.73 | $0.78 | +6.8% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $3.86 | $5.08 | +31.6% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $2.61 | $3.34 | +28.0% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $3.25 | $3.95 | +21.5% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $2.76 | $2.47 | -10.5% | ✗ MISS |
Latest News
Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $30
➖ NeutralFulgent Genetics Raises FY2025 GAAP EPS Guidance from $(2.10) to $(1.70) vs $(1.94) Est
📈 PositiveFulgent Genetics Raises FY2025 Adj EPS Guidance from $(0.35) to $0.30 vs $(0.35) Est; Raises FY2025 Sales Guidance from $320.000M to $325.000M vs $320.118M Est
📈 PositiveFulgent Genetics Q3 Adj. EPS $0.14 Beats $(0.22) Estimate, Sales $84.069M Beat $81.431M Estimate
📈 PositiveFulgent Genetics Reports Phase 2 Cancer Drug Results Ahead Of ESMO 2025 Presentation
➖ NeutralFulgent Genetics rises on earnings, revenue beat
📈 PositiveFrequently Asked Questions about FLGT
What is FLGT's current stock price?
What is the analyst price target for FLGT?
What sector is Fulgent Genetics, Inc. in?
What is FLGT's market cap?
Does FLGT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to FLGT for comparison